Joaquín Martínez‐López

Author

Hospital Universitario 12 De Octubre ORCID

Also Known As

A Rivero, A. Jiménez Velasco, Alberto Orfao, Ana Isabel Teruel, Anatoliy Gorbenko, Eulàlia Genescà, Franz Gruber, J A Martinez, J A Martínez Lopez, J López

1.5K

Publications

25.1K

Citations

H-Index

188

Concepts

All Affiliations

Hospital Universitario 12 De Octubre Centro de Investigación Biomédica en Red de Cáncer Instituto de Investigación Biomédica de Salamanca Clinica Universidad de Navarra Institut Català d'Oncologia

About

Joaquín Martínez‐López is an author at Hospital Universitario 12 De Octubre specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	79	6.7K
2	Health Sciences	21	34	3.5K
3	Engineering	15	17	940
4	Public Health	4	4	379
5	Natural Sciences	1	1	49

Joaquín Martínez‐López

318

Publications

20.9K

Citations

H-Index

Page 1

	Year	Citations
Teclistamab in Relapsed or Refractory Multiple Myeloma Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk, New England Journal of Medicine	2022	990
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Jesús F. San Miguel, Katja Weisel, Philippe Moreau, The Lancet Oncology Hematological MalignancyMedicineHematologyMyeloid NeoplasiaPharmacotherapy	2013	794
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma Juan Flores‐Montero, Luzalba Sanoja-Flores, Bruno Paiva, Leukemia	2017	626
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma Jesús F. San Miguel, Binod Dhakal, Kwee Yong, New England Journal of Medicine	2023	615
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial Johan Richter, Joëlle Guilhot, Franz Gruber, The Lancet Oncology Hematological MalignancyMedicineChronic Myeloid LeukaemiaMixed-phenotype Acute LeukemiaHematology	2018	587
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial Nathan Fowler, Michael Dickinson, Martin Dreyling, Nature Medicine Lymphoid NeoplasiaHematologyImmunologyPathologyElara Trial	2021	492
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma Michael R. Bishop, Michael Dickinson, Duncan Purtill, New England Journal of Medicine	2021	491
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Blood	2012	485
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf, Nature Medicine Hematological MalignancyMagnetismm-3 Trial ResultsMedicineBispecific AntibodySubcutaneous Elranatamab	2023	483
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López, The Lancet Oncology Hematological MalignancyElderly PatientsMedicineRandomised TrialHematology	2010	459

Page 1